Research programme: VEGF inhibitors - Amgen

Drug Profile

Research programme: VEGF inhibitors - Amgen

Alternative Names: AMG-273

Latest Information Update: 06 Apr 2011

Price : $50

At a glance

  • Originator Amgen
  • Class Antineoplastics
  • Mechanism of Action Angiogenesis inhibitors; Platelet-derived growth factor receptor antagonists; Protein tyrosine kinase inhibitors; Vascular endothelial growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 19 Apr 2009 Preclinical development is ongoing in USA
  • 08 Apr 2009 Preclinical pharmacodynamics data presented at the 100th Annual Meeting of the American Association for Cancer Research (AACR-2009)
  • 11 May 2007 Preclinical trials in Cancer in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top